Socazolimab

索卡佐利单抗

Report date: 2025/08/05 17:45:59

Base Information

Drug NameSocazolimab
Drug Alias NameSocazolimab重组全人抗PD-L1单抗注射液重组全人抗PD-L1单抗（兆科肿瘤）Recombinant human anti-PD-L1 monoclonal antibody (Zhaoke Oncology)首克注利单抗 +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed death-ligand 1 blockersAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsUterine Cervical NeoplasmsSmall Cell Lung CarcinomaEsophageal Neoplasms +[9] 
Global Approved IndicationsUterine Cervical Neoplasms
Approved Indications in ChinaUterine Cervical Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2023/12/19
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesZhaoke (Guangzhou) Oncology Pharmaceutical LtdSorrento Therapeutics Inc
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesLee’S Pharmaceutical Holdings LtdZhaoke (Guangzhou) Oncology Pharmaceutical Ltd
Inactive CompaniesLee'S Pharmaceutical LtdWuxi Biologics Co Ltd
Active IndicationsUterine Cervical NeoplasmsSmall Cell Lung CarcinomaCarcinoma, Transitional Cell +[5] 
Inactive IndicationsEsophageal NeoplasmsBile Duct NeoplasmsBiliary Tract Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksKEGG